Dr. Gauthier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-6956
Education & Training
Faculte Libre de Medecine de Lille, FranceClass of 2008
Certifications & Licensure
WA State Medical License 2014 - 2025
Clinical Trials
- A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Start of enrollment: 2022 Feb 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 7 citationsA novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy.Alexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, Rachel N Steinmetz, Henna A Di
Blood Advances. 2023-06-13 - 9 citationsCMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell Immunotherapy.Madeleine R. Heldman, Jimmy Ma, Jordan Gauthier, Riley A O'Hara, Andrew J. Cowan
Journal of Immunotherapy. 2021-08-09 - 2 citationsHuman herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients.Eleftheria Kampouri, Elizabeth M Krantz, Hu Xie, Sarah S Ibrahimi, Erika S Kiem
Blood. 2024-08-01
Abstracts/Posters
- Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant AbstractJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell TherapyJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical OutcomesJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021- Seattle Cancer Care Alliance to Present New Research at 62nd Annual Meeting of the American Society of HematologyDecember 4th, 2020
Combination Therapy Boosts Durability of CAR T-cell Response in Hematologic CancersJanuary 10th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
